{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T01:16:28Z","timestamp":1783646188403,"version":"3.55.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T00:00:00Z","timestamp":1686096000000},"content-version":"am","delay-in-days":402,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.therap.2021.12.015","type":"journal-article","created":{"date-parts":[[2021,12,28]],"date-time":"2021-12-28T04:09:29Z","timestamp":1640664569000},"page":"301-307","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Comparative study of the adverse event profile of hydroxychloroquine before and during the Sars-CoV2 pandemic"],"prefix":"10.1016","volume":"77","author":[{"given":"Pauline","family":"Lory","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9mence","family":"Lacroix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Sanchez-Pena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Romani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Grandvuillemin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2021.12.015_bib0110","series-title":"Chronologie de l\u2019action de l\u2019OMS face \u00e0 la COVID-19","author":"Organisation mondiale de la sant\u00e9","year":"2020"},{"key":"10.1016\/j.therap.2021.12.015_bib0115","series-title":"Avis relatif \u00e0 la prise en charge des cas confirm\u00e9s d\u2019infection au virus SARS-CoV2","author":"HCSP","year":"2020"},{"key":"10.1016\/j.therap.2021.12.015_bib0120","series-title":"Suivi des effets ind\u00e9sirables des m\u00e9dicaments utilis\u00e9s dans la prise en charge du COVID-19\u00a0\u2013\u00a0Chiffres cl\u00e9s","author":"ANSM","year":"2020"},{"key":"10.1016\/j.therap.2021.12.015_bib0125","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s40264-020-01034-y","article-title":"French Pharmacovigilance Network. French Pharmacovigilance Network. French Pharmacovigilance Public System and COVID-19 Pandemic","volume":"44","author":"Grandvuillemin","year":"2021","journal-title":"Drug Safety"},{"key":"10.1016\/j.therap.2021.12.015_bib0130","series-title":"Protocole d\u2019utilisation th\u00e9rapeutique de l\u2019hydroxychloroquine dans l\u2019infection par le coronavirus SARS-CoV-2","author":"ANSM","year":"2020"},{"key":"10.1016\/j.therap.2021.12.015_bib0135","series-title":"Institut Pierre Louis UMR S 1136, INSERM, UPMC, R\u00e9seau Sentinelles","year":"2020"},{"key":"10.1016\/j.therap.2021.12.015_bib0140","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.revmed.2013.10.334","article-title":"Physiopathologie du lupus syst\u00e9mique\u00a0: le point en 2014","volume":"35","author":"Mathian","year":"2014","journal-title":"Rev Med Intern"},{"key":"10.1016\/j.therap.2021.12.015_bib0145","series-title":"Polyarthrite rhumato\u00efde","author":"Vidal\u00ae","year":"2020"},{"key":"10.1016\/j.therap.2021.12.015_bib0150","series-title":"COVID-19. Point \u00e9pid\u00e9miologique hebdomadaire","author":"Sant\u00e9 Publique France","year":"2020"},{"key":"10.1016\/j.therap.2021.12.015_bib0155","series-title":"COVID-19 weekly surveillance report. Data for the week of 11\u201317 May 2020 (Epi week 20)","author":"World Health Organization","year":"2020"},{"key":"10.1016\/j.therap.2021.12.015_bib0160","series-title":"R\u00e9sum\u00e9 des caract\u00e9ristiques du produit de PLAQUENIL\u00ae","author":"ANSM","year":"2020"},{"key":"10.1016\/j.therap.2021.12.015_bib0165","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1002\/hep.31480","article-title":"Abnormal liver function tests in patients with COVID-19: relevance and potential pathogenisis","volume":"72","author":"Bertolini","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.therap.2021.12.015_bib0170","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.therap.2020.05.002","article-title":"\u201cOff-label\u201d use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers","volume":"75","author":"G\u00e9rard","year":"2020","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2021.12.015_bib0175","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/cts.12883","article-title":"Insights on the evidence of cardiotoxicity of hydroxychloroquine prior and during COVID-19 epidemic","volume":"14","author":"Romani","year":"2021","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.therap.2021.12.015_bib0180","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.therap.2020.05.010","article-title":"French Society of Pharmacology and Therapeutics (SFPT). Chloroquine and hydroxychloroquine in the management of COVID-19: Much kerfuffle but little evidence","volume":"75","author":"Roustit","year":"2020","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2021.12.015_bib0185","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1161\/CIRCULATIONAHA.120.048238","article-title":"Cardiovascular toxicities associated with hydroxychloroquine and azithromycin. an analysis of the World Health Organization pharmacovigilance database","volume":"142","author":"Nguyen","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.therap.2021.12.015_bib0190","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1007\/s00228-020-02920-1","article-title":"Serious adverse drug reactions with hydroxychloroquine: a pharmacovigilance study in Vigibase\u00ae","volume":"76","author":"Montastruc","year":"2020","journal-title":"Eur J Clin Pharmacol"},{"issue":"7\u20138","key":"10.1016\/j.therap.2021.12.015_bib0195","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1007\/s12471-020-01429-7","article-title":"Chloroquine-induced QTc prolongation in COVID-19 patients","volume":"28","author":"van den Broek","year":"2020","journal-title":"Neth Heart J"},{"issue":"10245","key":"10.1016\/j.therap.2021.12.015_bib0200","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/S0140-6736(20)31528-2","article-title":"Retraction and republication: cardiac toxicity of hydroxychloroquine in COVID-19","volume":"396","author":"Funck-Bretano","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.therap.2021.12.015_bib0205","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1001\/jamacardio.2020.1017","article-title":"Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19)","volume":"5","author":"Guo","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.therap.2021.12.015_bib0210","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","article-title":"Under-reporting of adverse drug reactions: a systematic review","volume":"29","author":"Hazell","year":"2006","journal-title":"Drug Saf"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595721002675?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595721002675?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T18:54:53Z","timestamp":1758567293000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595721002675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S0040595721002675"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2021.12.015","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative study of the adverse event profile of hydroxychloroquine before and during the Sars-CoV2 pandemic","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2021.12.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique.","name":"copyright","label":"Copyright"}]}}